Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
20 October 2023 | Story Samkelo Fetile
2023 UFS Thought-Leader Webinar Series

The University of the Free State (UFS) is pleased to present a panel discussion titled, Student protest action, politics, and higher education, which is part of the 2023 Thought-Leader Webinar Series. Join Prof Adam Habib and Dr Max Price for a discussion about their respective experiences in leadership positions during the #RhodesMustFall and #FeesMustFall student protest movements, the lessons learnt during these tumultuous times, and how these events continue to influence the current landscape in the higher education sector in South Africa and further afield. The discussion will reflect on their recent books Rebels and Rage: Reflecting on #FeesMustFall, and Statues and Storms, and will be facilitated by Prof Francis Petersen, the Vice-Chancellor and Principal of the UFS.


Date:   Tuesday 21 November 2023

Time: 13:00-14:30

Click to view document WATCH: vimeo.com/kovsies/tls23

For further information, contact Alicia Pienaar at pienaaran1@ufs.ac.za.


Some of the topics discussed by leading experts in 2022 included, Crime in South Africa – who is to blame; Are our glasses half full or half empty; What needs to be done to power up South Africa; A look into the future of South Africa. This year’s webinar series commenced with a discussion on Threats to South Africa’s stability and security challenges, followed by A culture of acceptance – is this South Africa’s greatest threat? and The need for a global and regional plan / approach to respond to the consequences of the Russia-Ukraine war.


Facilitator:

Prof Francis Petersen

Vice-Chancellor and Principal, UFS

 

Panellists:

Prof Adam Habib

Director: School of Oriental and African Studies, University of London

 

Dr Max Price

Emeritus Vice-Chancellor, University of Cape Town; academic and consultant

 

Bios of speakers:

 

Prof Adam Habib

Prof Adam Habib is an academic, researcher, activist, administrator, and well-known public intellectual. A Professor of Political Science, Prof Habib has more than 30 years of academic, research, and administration expertise, spanning five universities and multiple local and international institutions.

Prior to his appointment as Director of SOAS, he was Vice-Chancellor and Principal of the University of the Witwatersrand (Wits) in Johannesburg, South Africa between 2013 and 2020. He has also served as Deputy Vice-Chancellor of Research at the University of Johannesburg, Executive Director of Democracy and Governance at the Human Sciences Research Council, and as Director of the Centre for Civil Society and Professor of Development at the University of KwaZulu-Natal. He is widely published, including his two well-received monographs, South Africa's Suspended Revolution: Hopes and Prospects and Rebels and Rage: Reflecting on #FeesMustFall.

Prof Habib’s academic contributions resulted in his election to the American Academy of Arts and Sciences, in addition to serving as a fellow of both the African Academy of Sciences and the Academy of Science of South Africa. He also serves on the Council of the United Nations University.

 

Dr Max Price

Dr Max Price was appointed Vice-Chancellor of the University of Cape Town in July 2008, completing his ten-year term in June 2018. During the first seven years of his term, UCT experienced growth and success in research and teaching, as well as global recognition. This continued during the last three years but was overshadowed by the Rhodes Must Fall and Fees Must Fall protests during 2015 to 2017. Dr Price led the university through these storms and back to safe harbour in 2018.

Dr Price studied Medicine at the University of the Witwatersrand (Wits), during which time he became deeply involved in student politics, becoming SRC president a year after the Soweto uprising. He subsequently did a PPE degree at Oxford as a Rhodes Scholar. Following clinical work in academic and rural hospitals in South Africa, he gained a master’s degree in Community Health at the London School of Hygiene and Tropical Medicine, and then worked as an academic in the areas of health policy and economics, rural health services, and health science education.

He was dean of the Faculty of Health Sciences at Wits for ten years. He now consults in public health, higher education, strategic leadership, and advises foundations on grant making. He is currently a scholar in residence at the Atlantic Institute. He is the author of Statues and Storms: Leading through change, published in 2023.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept